

YALE CENTER FOR THE SCIENCE OF CANNABIS AND CANNABINOIDS

ANNUAL REPORT 2024 - 2025

*A hub for groundbreaking research,
dissemination of information, and ed-
ucation in the science of cannabis and
cannabinoid science.*

TABLE OF CONTENTS

MISSION STATEMENT	4
A WORD FROM THE DIRECTOR	5
ABOUT OUR WORK	6
IMPACT OF CANNABIS SCIENCE	7
PROTECTING MENTAL HEALTH	8
IMPROVING PUBLIC SAFETY	8
HELPING PEOPLE QUIT CANNABIS	8
GIVING PEOPLE INFORMED CHOICE	9
CHANGING CLINICAL AND SCIENTIFIC PRACTICES	9
PILOT FUNDING PROGRAM	10

TABLE OF CONTENTS CONT.

PILOT AWARDEES 12

PILOT PROJECT METRICS 13

CURRENT RESEARCH 14

FACULTY 16

HIGHLIGHTS OF THE YEAR 17

LOOKING AHEAD 18

RECOGNITION & GRATITUDE 19

HOW TO GET INVOLVED 19

MISSION STATEMENT

The Yale Center for the Science of Cannabis and Cannabinoids (YC-SCAN²), established in 2023, was created to advance the understanding of cannabis and its derivatives, often referred to as cannabinoids. This innovative Center is a hub for groundbreaking research, dissemination of information, and education in the field of cannabis and cannabinoid science. Our mission is to conduct comprehensive research on the risks and potential therapeutic applications of cannabis and cannabinoids, and to inform public policy based on our findings.

At YC-SCAN², we focus on thorough scientific research and strive to find science-based answers to critical questions concerning the risks and potential medical benefits associated with cannabis and its derivatives. We are also dedicated to translating the knowledge we gain into helpful, practical applications that could enhance patient care and inform public policy.

The Center supports pilot projects from Yale-affiliated researchers, aiming to bridge the gap between basic and clinical research. These projects form the foundation for larger funding applications to NIH and other agencies. YC-SCAN² also encourages multidisciplinary studies into the effects of cannabis and cannabinoids, combining molecular neuroscience, genetics, electroencephalography, imaging, and psychopharmacology. We are deeply committed to training the next generation of scientists and clinicians to carry forward this important work in the emerging field of cannabis science.

RESEARCH

Our research spectrum is broad and comprehensive, encompassing everything from a basic understand of cannabis and cannabinoids, to conducting advanced clinical trials exploring their potential benefits and risks.

DISSEMINATION OF INFORMATION

YC-SCAN² will independently and in partnership with other relevant organizations to provide regular updates to the scientific community and public.

EDUCATION

YC-SCAN² will partner with existing training programs within the Yale Community to train fellows and postdocs in cannabis and cannabinoid research under the mentorship of Yale investigators with relevant expertise.



A WORD FROM THE DIRECTOR

Deepak Cyril D'Souza, MBBS, MD

Vikram Sodhi '92 Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director, Neurobiological Studies Unit, VACHS; Director, VA-CMHC Schizophrenia Research Clinic; Director, Yale Center for the Science of Cannabis and Cannabinoids ; Chair, Research and Development Committee, VA Connecticut Healthcare System.

It is my privilege to present the first annual report of the Yale Center for the Science of Cannabis and Cannabinoids (YC-SCAN²). Cannabis use is increasing nationwide, potency is rising, and the public conversation continues to evolve.

Our mission is to bring clarity to this complex landscape through evidence-based science—illuminating both the risks and potential therapeutic applications of cannabis and its derivatives. Towards that end, we launched a robust pilot funding program, awarding over \$600,000 to 14 Yale investigators pursuing innovative projects spanning neurodevelopment, mental health, pharmacology, genetics, imaging, and treatment. In this climate of uncertainty around grant funding, we are hopeful that this funding will support important work, and importantly the work of junior investigators.

In an effort to further engage and promote junior researchers who are interested in cannabis or cannabinoid research, we awarded travel awards to trainees and others to attend the 2025 Gordon Research Conference on Cannabinoid Function in the CNS. This week-long conference will give junior investigators an unique opportunity to present their work, discuss cutting-edge ideas, and build collaborative relationships within the field. This travel award was named in memory of Patrick Skosnik, PhD, who was Associate Professor of Psychiatry at Yale School of Medicine. Patrick spent most of his academic career conducting research on cannabis and cannabinoids before his untimely death in 2024.

We initiated a monthly webinar series on cannabis and cannabinoids that connects scientists, clinicians, students, and the broader public. The webinar has been well-attended and has led to collaborations between attendees.

Faculty affiliated with the Center have continued to produce high-impact work on topics ranging from cannabis' acute effects on brain function to new treatment approaches for cannabis use disorder.

Looking ahead, we aim to expand our research network, host our inaugural YC-SCAN² symposium, and deepen our community engagement initiatives. These efforts will build on the foundation we have laid this year bridging basic science, clinical insight, and public health. I am grateful to our dedicated faculty, staff, trainees, collaborators, and supporters whose contributions make this work possible. Together, we are committed to advancing knowledge that informs policy, improves care, and empowers individuals to make informed choices.

Deepak Cyril D'Souza, MBBS, MD
Director, Yale Center for the Science of Cannabis and Cannabinoids

ABOUT OUR WORK

Dr. Deepak D’Souza’s research lab has advanced our understanding of how cannabis affects the brain, demonstrating its links to psychosis, cognitive impairment, and driving risks, while also pioneering treatments for cannabis use disorder. His lab’s findings have helped inform public health policies, clinical practices, and empowered individuals to make safer, more informed decisions about cannabis use.

Early Neurophysiology: THC’s Acute Brain Effects

In landmark human lab studies, D’Souza’s team administered intravenous THC and measured changes in event-related potentials, neural oscillations (e.g., disrupted γ -band EEG), memory, attention, and psychotomimetic symptoms. They demonstrated dose-dependent acute disruptions in sensory processing and cognition. These experiments helped clarify that THC—beyond its subjective “high”—can transiently impair memory, attention, and sensory integration, providing a mechanistic link to cognitive dysfunction and psychosis.

Chronic Heavy Use & Psychosis Phenotypes

Studying a unique Jamaican cohort of individuals chronically using cannabis since early adolescence, D’Souza’s team showed significant cognitive decrements—working memory, attention, psychomotor speed, flexibility—and increases in schizotypal traits (“odd beliefs,” “magical thinking”) compared to matched controls. Longitudinal follow-up showed progressive memory decline, emphasizing that sustained heavy use may lead to persistent, real-world cognitive and psychosis-relevant changes.

Tolerance in Regular Users

In frequent cannabis users, the psychotomimetic, memory-disrupting, perceptual, and endocrine effects of THC were found to be blunted compared to occasional users. This was a crucial insight: regular exposure leads to tolerance of negative cognitive and psychological effects—though the euphoric “high” remained intact—deepening our understanding of cannabinoid pharmacodynamics.

Endocannabinoid Modulation & BDNF

Early work from the lab found that THC alters levels of Brain-Derived Neurotrophic Factor (BDNF) in humans, pointing to post-drug molecular changes that could underlie cognitive and structural brain effects.

Driving Safety and Polysubstance Effects

D’Souza pioneered combined IV THC + alcohol studies, using driving simulators and ERP monitoring to show synergistic impairments in simulated driving performance—insights critical for public safety and evidence-based DUI guidelines.

IMPACT ON CANNABIS SCIENCE

The labs’ rigorous, translational work—from lab-based human models to field studies and clinical trials—has been pivotal in transforming cannabis discourse from anecdotal/opinion-based to data-driven science. The labs research has shaped how regulators, clinicians, and the public understand cannabis: not only its intoxicating aspects but its cognitive, psychiatric, and neurobiological effects, as well as paths toward therapeutic intervention.

Acute THC Effects	Shown to impair EEG oscillations, memory, perception, driving—supporting objective measures of impairment.
Tolerance	Demonstrated that repeated use blunts negative but not euphoric effects—distinguishing pharmacological tolerance patterns.
Chronic Heavy Use	Linked long-term use to cognitive decline and psychosis-like traits—informing public health policy and adolescent risk.
Neurobiology	Revealed molecular changes (e.g. BDNF modulation) underlying neuroplastic effects of cannabinoids.
Treatment Potential	Introduced FAAH-inhibitors as a non-intoxicating therapeutic pathway for dependence.
Policy & Prevention	Provided experimental data behind DUI laws and identified psychiatric risks connected to potency and formulation (Δ -8, synthetics).

PROTECTING MENTAL HEALTH



The research lab has worked on various studies that have significantly helped people by advancing science, shaping policy, and informing clinical practice. THC studies have shown that THC can induce psychosis-like symptoms—especially in vulnerable individuals. Study findings have raised awareness about cannabis related psychosis, particularly in adolescents and those with a family history of schizophrenia. Have helped clinicians counsel patients on potential psychiatric risks, and Informed public health messaging, especially about high-potency cannabis and synthetic cannabinoids like K2 and Spice, which have stronger

links to psychosis. This has impacted vulnerable populations from harm and help families, youth, and care providers so they are better equipped to recognize and mitigate mental health risks from heavy or early cannabis use.

IMPROVING PUBLIC SAFETY

Providing the public guidance on the real risks of cannabis impaired driving, potentially saving lives, research have contributed to public safety campaigns about driving under the influence of cannabis. Supported evidence based policy and DUI law, helping reduce traffic fatalities and impaired driving incidents.



HELPING PEOPLE QUIT CANNABIS

By identifying neurobiological mechanisms of cannabis dependence and piloting new treatments (e.g., FAAH inhibitors that elevate natural endocannabinoids), the research team has paved the way for new medications to treat cannabis use disorder (CUD). Helped shift the conversation on cannabis dependence and is now more widely understood as a legitimate condition deserving medical intervention. This has impacted people struggling with problematic cannabis use who will soon have more effective, biologically informed options for support and treatment.

GIVING PEOPLE INFORMED CHOICE



By showing how THC affects memory, attention, perception and emotion, even in healthy users, our centers research has helped people understand what's happening in their brain when they use cannabis and has helped people make better decisions about when, how and how much to use—especially in contexts like work, school and social situations. This research has resulted in helping users make more informed choices, knowing the cognitive effects are real and measurable, not just anecdotal.

CHANGING CLINICAL AND SCIENTIFIC PRACTICES

The research centers' controlled human studies are rare and difficult to conduct, the lab has set a scientific gold standard for cannabis research, influencing how scientists study the brain and drug effects. Data has been produced to guide clinicians in understanding cannabis interactions with psychiatric medications or mental health conditions, giving researchers, therapists and physicians more reliable tools to assess and treat patients with cannabis-related concerns.



Y-C-SCAN² PILOT PROGRAM

In 2023, The Yale School of Medicine announced the creation of a Center for the Science of Cannabis and Cannabinoids (Y-SCAN2). The launch of Y-SCAN2 comes at a time of rapid legalization, and commercialization of cannabis across the United States and beyond.

The goal of Y-SCAN2 is to establish a self-sustaining program of research on the science of cannabis and cannabinoids. One intermediate-term goal is to submit a NIH Center grant application with a theme that would broadly span the acute and chronic effects of cannabis and cannabinoids on neurodevelopment and mental health. Towards that end, Y-SCAN2 was pleased to announce pilot grants to generate data that potentially could lead to further research and funding.

A panel of reviewers with expertise relevant to the mission of Y-SCAN2 was established to review pilot grants. The level of expertise and experience includes research in Addiction, Cognition, Driving, EMA, Genetics, Imaging, Molecular Science, Neurodivergence, Organoids, Pain, Perinatal, Prenatal, Psychosis and Treatment.

The purpose of this funding opportunity is to provide pilot awards for new initiatives in translational and interdisciplinary research that focus on important aspects of human disease or the science of teams. Up to \$50,000 research support per year for up to 2 years. LOI required to determine eligibility for full application.

The RFP was announced in February 2024 with a due date of June 2024. The center had over 32 applications submitted during the open period all of which were highly competitive and innovative. In November 2024 Y-C-SCAN2 announced 12 projects have been awarded pilot funding, with a December start date.

PANEL OF REVIEWERS



Godfrey D. Pearlson, M.D., Professor of Psychiatry and Neuroscience



Christopher Pittenger, MD, Ph.D., Mears & Jameson Professor of Psychiatry




Jibran Khokhar, Ph.D., Associate Professor Anatomy and Cell Biology



Susumu Tomita, Ph.D., Professor of Cellular and Molecular Physiology and Neuroscience



Jessica Cardin, Ph.D., Professor of Neuroscience



Arielle Baskin-Sommers, Ph.D., Associate Professor of Psychology and of Psychiatry




Ralph DiLeone, Ph.D., Professor of Psychiatry and of Neuroscience




Jamie McPartland, Ph.D., Harris Professor in the Child Study Center




Marc Potenza, Ph.D., MD, Professor of Psychiatry and professor in the Child Study Center and of Neuroscience



Suchitra Krishnan-Sarin, Ph.D., Professor of Psychiatry



Mike Stevens, Ph.D., Professor of Psychiatry



Joao De Aquino, MD, Assistant Professor of Psychiatry



Suhas Ganesh, MD, Assistant Professor of Psychiatry

MILESTONES

Y-C-SCAN2 has developed a comprehensive Pilot Program up to and including strategic planning of funded projects.

October 2023

Y-C-SCAN2 opens with an initial plan to start a Pilot Funding Program



June 2024

Pilot application submission due. There were a total of 32 applications submitted within a variety of areas of research



November 2024

Finalist evaluated and decision made based on multiple criteria including projects potential for additional funding




January 2025

Launch of webinar series. Webinars to serve as a platform for researchers to discuss their pilot projects with a larger audience



November 2025

Review of progress reports, projects achievements and final selection of second year funding awardees



& TIMELINE

...ive plan for tracking milestones for its
...es for additional outreach and promotion
...projects.

February 2024
RFP announcement for Pilot Funding applications. Awardees will be granted up to \$100k each over 2 years.

September 2024
Panel of Reviewers established. Each reviewer was assigned projects coinciding with their area of expertise. Reviewers provided comprehensive feedback to be shared with all applicants

December 2024
First year funding dollars available for distribution to awardees. Marks the official start date for pilot projects

October 2025
Eleven Month Pilot Project progress reports due. Awardees are required to submit progress reports to determine eligibility for second year funding

December 2025
Second year funding dollars available for distribution for second year awardees.

OVERALL PROJECT SUBMISSIONS

A total of 32 applications were submitted to the Pilot Funding Program. Projects addressed different topics within the study of cannabis and cannabinoids. Thirteen Projects involved animal research, eighteen projects involved human research and one project involved both animal and human research.



56% Clinical Research

18 of the 32 approved pilot projects involve human research



41% Basic Research

13 of the 32 approved pilot projects involve animal research




3% Both Basic & Clinical

13 of the 32 approved pilot projects involve animal research

OVERALL SUBJECT VARIATION

The pilot applications incorporated 15 different areas of research such as Treatment, Psychosis, Addiction, EMA, Pain, Driving, imaging, Organoids, Neurodivergence, Perinatal, Prenatal, Genetics, Molecular science, Pharmacology and Cognition. The highest percentage of applications were related to Cognitions with 16% of projects, followed by Prenatal research with 13% and Genetics, Treatment and Pharmacology with 9% of overall submissions.



AWARDEES & PILOT PROJECTS



Nicola Micali, Ph.D., Associate Research Scientist

Pilot Project: Defining the impact of prenatal exposure to cannabinoids on primate brain development



Alfred P. Kaye MD, PhD, Assistant Professor, Department of Psychiatry

Pilot Project: Computational behavioral and in vivo electrophysiological characterization of the emerging cannabinoid delta-8-THC



Kristen Brennand, PhD, Professor, Department of Psychiatry

Pilot Project: Deciphering the impact of prenatal exposure to THC on psychiatric disorder risk



Ruth H. Asch, Ph.D., Associate Research Scientist

Pilot Project: Establishing a preclinical model to investigate mGlu5 receptor mechanisms in cannabis use



Godfrey D. Pearlson, M.D., Professor of Psychiatry and Neuroscience

Pilot Project: Oral Beta-caryophyllene for the Treatment of Chronic Reflex Sympathetic Dystrophy Pain: An Observational Study



Alicia Che, Ph.D., Assistant Professor

Pilot Project: Developmental Mechanisms for the Effects of Prenatal Cannabinoid Exposure on Prefrontal Circuitry



Ruu Harn Cheng, Ph.D., Postdoctoral Associate

Pilot Project: Cognitive mechanisms of perceptual and reward processing in youth with and without cannabis use



Renato Polimanti, PhD, Associate Professor of Psychiatry and Epidemiology

Pilot Project: Brain-wide pleiotropy investigation of cannabis use vs. cannabis use disorder



Michael J. Higley, MD, Ph.D., Associate Professor of Neuroscience

Pilot Project: Consequences of developmental cannabinoid exposure for GABAergic circuits in the prefrontal cortex



Mohini Ranganathan, MBBS, Staff Psychiatrist, VACHS; Assoc. Prof., Dept. of Psychiatry

Pilot Project: Multimodal Evaluation of Cannabis Use Impact on Schizophrenia Risk



Albert Powers, M.D., Ph.D., Associate Professor & **Jose Cortes-Briones, Ph.D.**, Assistant Professor of Psychiatry

Pilot Project: Do the brain states produced by cannabis mimic those of the earliest phases of psychosis?



Christopher Pittenger, MD, Ph.D., Mears & Jameson Professor of Psychiatry & **Cheng Jiang, Ph.D.**, Associate Research Scientist

Pilot Project: Impact of Perinatal Cannabinoid Exposure on the Histaminergic System: Relevance to Tic Disorders



AWARDED PROJECTS RESEARCH TYPE



42% Clinical Research


5 of the 12 approved pilot projects involve human research




58% Basic Research

7 of the 12 approved pilot projects involve animal research

Late Career




9 Areas of Research




MEASURES OF SUCCESS


A primary measure of success for pilot projects will be based on the projects potential for generating additional funding from other sources. YC-SCAN2's pilot reviewers identified each projects overall potential for generating additional funding based on multiple criteria. The awarded projects have a probability of 50%-80% potential to generate additional funding.



70% - 80%



60% - 69%



50% - 59%



CURRENT RESEARCH

Acute effects of THC in older adults

This study investigates the acute effects of THC in older adults within the broader context of rising cannabis use and potency. With evidence linking chronic cannabis exposure to reduced hippocampal synaptic density and impaired verbal memory, the study aims to assess whether these deficits improve following four weeks of abstinence in individuals with Cannabis Use Disorder (CUD). By examining changes in brain structure and function using advanced PET imaging, the research seeks to clarify the relationship between cannabis exposure, synaptic health, and cognitive performance.



Psilocybin induced neuroplasticity in the treatment of major depressive disorder

This study explores how psilocybin-assisted therapy affects the brain and mind in individuals with major depressive disorder, hypothesizing that the treatment will lead to neuroplastic changes that correspond with reduced depressive symptoms.



A Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain

This proof-of-concept trial evaluates the safety, tolerability, and effectiveness of cannabis derivatives—THC, CBD, and their combination—for treating chronic diabetic peripheral neuropathy (CDNP) in U.S. Veterans. Conducted across five VA medical centers, the randomized, double-blind, placebo-controlled study will assess whether these compounds reduce pain more effectively than placebo, while also monitoring functional, emotional, and quality-of-life outcomes. Results aim to inform future research and provide high-quality evidence on cannabis-based treatments for Veterans and potentially civilians with CDNP.

Do hippocampal synaptic density deficits in cannabis use disorder improve following abstinence?

This study investigates whether hippocampal synaptic density deficits observed in individuals with Cannabis Use Disorder (CUD) improve following four weeks of abstinence. Using advanced PET imaging with the tracer [¹¹C]UCB-J, researchers will assess changes in synaptic vesicle density and their relationship to verbal memory performance, aiming to better understand the brain's capacity for recovery after chronic cannabis exposure.

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

This study examines the genetics of Cannabis Use Disorder (CanUD) and individual responses to cannabinoids in the context of a rapidly evolving cannabis landscape marked by increased availability, potency, and societal acceptance. As cannabis use rises—especially among young adults—and the risk of CanUD and psychosis grows, understanding the genetic factors that influence susceptibility and treatment response is critical to addressing the emerging public health challenges.

ADDITIONAL STUDIES

- In vivo study of THC-induced immune genome changes at single cell resolution in HIV-infected humans
- Imaging mGluR5 and synaptic density in psychiatric disorders
- Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
- A Longitudinal study of the effects of cannabis exposure on neuro-development in adolescents and young adults



YC-SCAN² FACULTY



Anahita Bassir Nia, MD

Assistant Professor of Psychiatry; Research Psychiatrist, VA National Center for PTSD



Mohini Ranganathan, MBBS

Associate Professor of Psychiatry



Alicia Y Che, PhD

Assistant Professor of Psychiatry; Director of Graduate Admissions, Interdepartmental Neuroscience Program



Ashley Schnakenberg Martin, PhD

Associate Professor



Jose Cortes-Briones

Assistant Professor of Psychiatry



Rajita Sinha, PhD

Foundations Fund Professor of Psychiatry and Professor in the Child Study Center and of Neuroscience; Deputy Chair of Psychiatry for Psychology, Psychiatry; Director, Yale Interdisciplinary Stress Center; Chief, Psychology Section in Psychiatry



Joel Gelernter, MD

Foundations Fund Professor of Psychiatry and Professor of Genetics and of Neuroscience; Director, Division of Human Genetics (Psychiatry)



Stephanie Wemm, PhD

Associate Research Scientist, Psychiatry



Rajiv Radhakrishnan, MBBS, MD, FAPA

Associate Professor of Psychiatry; Associate Professor, Radiology and Biomedical Imaging; Co-Medical Director, Yale PET Center; Affiliated Faculty, Yale Institute for Global Health



Ke Xu, MD

Professor of Psychiatry; Director of Stress Epigenetics, Yale Stress Center



Michael Stevens, PhD

Professor Adjunct in Psychiatry; Adjunct Professor of Psychiatry; Director, Clinical Neuroscience and Development Laboratory at Olin Neuropsychiatry Research Center; Director, Child & Adolescent Research, The Institute of Living



Joao P. De Aquino, MD

Assistant Professor of Psychiatry; Assistant Chief of Inpatient Psychiatry, Clinical Neuroscience Research Unit (CNRU), Psychiatry; Assistant Director for Research Affairs, Clinical Neuroscience Research Unit (CNRU), Psychiatry

SCIENTIFIC ADVISORY BOARD

- * Professor Ken Mackie
- * Professor Sachin Patel
- * Professor Sir Robin Murray
- * Professor Godfrey Pearlson

Highlights of the Year



WEBINARS & SEMINARS

In January 2025 YC-SCAN² initiated a monthly webinar and seminar program. The program partners with existing training programs within the Yale Community to train fellows and postdocs in cannabis and cannabinoid research under the mentorship of Yale investigators with relevant expertise. Since its initiation, the program has been able to reach out to communities outside of Yale including other research centers, regional community programs and the general public.



SPEAKERS AND TOPICS


Yasmin Hurd, PhD: Cannabis Pathways to and from Addiction.

Romina Mizrahi, MD, PhD: Cannabis Effects on Microglia, Astroglia and Synaptic Density

Lena Palaniyappan, MD, PhD & Jessica Ahearns: Dope, Dopamine and Delusions

Ryan Bogdan, PhD: Behavioral and dBrain Correlates of Children with Prenatal Cannabis Exposure

Matthew Albaugh, PhD: MRI-Assessed Longitudinal Brain Changes Linked to Adolescent and Early Adult Cannabis Use



STUDENT VOLUNTEER PROGRAM

In 2025 the center accepted its first group of students into its student volunteer program. The program's mission is to provide students with hands-on experience working on cannabis research studies. The center is looking to expand this program and offer more students with research experience and mentorship opportunities.

PILOT FUNDING PROGRAM

In 2024 YC-SCAN² has granted over \$600,000 to 14 Yale School of Medicine researchers for innovative projects to understand the impact of cannabis and cannabinoids on neurodevelopment and mental health.

LOOKING AHEAD

The Yale Center for the Science of Cannabis and Cannabinoids (YC-SCAN²), is looking into the future with plans to expand and grow its influence in the science of cannabis research. With the hard work of our staff and faculty, we have been able to accomplish many things in the 2024 & 2025. With the support of our colleagues we hope to achieve the following initiatives.



YC-SCAN² SYMPOSIUM

Preliminary plans are underway for the center's inaugural symposium. Slated for April 2026, the center is planning to organize a day-long conference that will invite researchers, students, physicians, community members, educators, government officials and law enforcement officials to learn more about the science of cannabis and cannabinoids. This event will offer a space for presentations, panels, workshops and networking for anyone who wants to learn and get more involved in the field of cannabis and cannabinoids.

MULTI-CENTER NETWORK

One of the center's missions is to become a hub for other centers to collaborate. In 2026/2027 the center plans on furthering their plans to connect with other cannabis research centers in order to develop a robust network of centers with similar missions to support and share work, findings and resources where able. Collaboration includes multi-center research studies and a networking alliance.



COMMUNITY ENGAGEMENT AND EDUCATION INITIATIVE

The Center plans on expanding on its mission to disseminate information by developing its community education and engagement initiatives. This initiative will incorporate community advocacy and cannabis education resources for members of the local community including educators and social workers, with goals to expand on a larger scale.

RECOGNITIONS & GRATITUDE

THE WALLACE FOUNDATION

We extend our deepest gratitude to the Wallace Foundation for their generous support of our center and its mission. Their commitment has been instrumental in enabling us to advance cutting-edge research into psychedelic medicines, exploring their potential to transform mental health treatment. With the Foundation's partnership, we are empowered to pursue rigorous, impactful science that may offer new hope for individuals affected by complex psychiatric conditions. We are truly grateful for their belief in our work and shared vision for a healthier future.

VIKRAM SODHI

We are sincerely grateful to Vikram Sodhi for his generous support of our center and its mission. His commitment has played a vital role in advancing our research into psychedelic medicines, helping us explore innovative approaches to treating mental health conditions. With his support, we are able to pursue rigorous scientific inquiry and generate knowledge that holds the potential to improve countless lives. We deeply appreciate his partnership and belief in our vision for transformative mental health care.

PATRICK D. SKOSNIK

We are deeply grateful to Dr. Patrick Skosnik for his lasting contributions to our center's mission—his scientific insight, mentorship, and unwavering dedication to advancing research in cannabinoids and psychedelics continue to inspire us.

CHRISTINA LUDDY

We are deeply grateful to Christina Luddy for her many years of dedicated work, compassion, and brilliance—her warmth and contributions will be remembered always.

HOW TO GET INVOLVED

YC-SCAN² supports and welcomes collaboration. If you are interested in getting involved with the center and its mission, please contact:

Program Manager Wendy Agudo, MA, MBA at wendy.agudo@yale.edu

Director Deepak D'Souza, MD, PhD at deepak.dsouza@yale.edu



